IONS Ionis Pharmaceuticals Inc.

51.32
-0.51  -1%
Previous Close 51.83
Open 51.54
Price To book 29.67
Market Cap 6381882793
Shares 124,354,692
Volume 1,094,825
Short Ratio 10.36
Av. Daily Volume 1,255,429

SEC filingsSee all SEC filings

  1. 8-K - Current report 171049664
  2. 8-K - Current report 171025738
  3. S-8 - Securities to be offered to employees in employee benefit plans 171015978
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171015883
  5. 8-K - Current report 171013237

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 completion of enrollment noted June 22, 2017. Top-line data due around the end of 2017.
IONIS-HTT Rx
Huntington's Disease
Phase 1/2 interim data released November 2016.
IONIS-ANGPTL3-LRx
Cardiovascular disease
Phase 1/2 ongoing
IONIS-DMPK-2.5Rx
Myotonic Dystrophy Type 1 (DM1)
Phase 3 data released May 15, 2017 - primary endpoint met but with safety concerns.
Inotersen (IONIS-TTRRx)
NEURO-TTR - familial amyloid polyneuropathy (FAP).
Approved December 23, 2016.
SPINRAZA - Nusinersen
Spinal muscular atrophy (SMA)
Phase 2 data released November 2016.
IONIS-FXIRx
End-stage renal disease
Phase 2 data released 3Q 2015
IONIS-APO(a)Rx
High lipoprotein(a), or Lp(a)
Phase 2 data released January 4, 2016.
IONIS-GCGRRx
Type 2 diabetes
Phase 2 released Feb 2015. Achieved statistically significant results but data released was as of 36 weeks rather than 27 weeks for the primary endpoint
IONIS-PTP1BRx
Type 2 diabetes
Partner GSK announced May 2016 decision not to be proceed with Phase 3 outcome trial
Inotersen (IONIS-TTRRx)
CARDIO-TTR - Cardiomyopathy form of TTR amyloidosis.

Latest News

  1. Ionis Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : IONS-US : September 22, 2017
  2. Alnylam Is Entering 'New Chapter,' But Ionis Still Has A Chance
  3. Today's Research Reports on Trending Tickers: DelMar Pharmaceuticals and Ionis Pharmaceuticals
  4. Alnylam Rockets On Strong Rare-Disease Drug Data; Ionis Tanks
  5. Why Alnylam Pharmaceuticals, Inc. Skyrocketed and Ionis Pharmaceuticals Inc Sank Today
  6. Billionaire George Soros' Fund Bought These 3 Pharma Stocks: Should You?
  7. See what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.
  8. Akcea and Ionis Announce Filing of New Drug Submission for Volanesorsen to Health Canada
  9. New Data Presented at European Society for Medical Oncology Meeting Demonstrate Antitumor Activity with IONIS-STAT3-2.5 Rx in Combination with Imfinzi
  10. Ionis Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : IONS-US : September 1, 2017
  11. Today's Research Reports on Trending Tickers: Nektar Therapeutics and Ionis Pharmaceuticals Inc.
  12. Ligand Pharmaceuticals Focuses on Increasing Returns for Shareholders
  13. Featured Company News - Ionis Earns Regulatory Milestone Payment from Biogen for SPINRAZA
  14. Technology Platforms and Research Programs Drive LGND’s Partnerships
  15. Akcea and Ionis Announce Submission of New Drug Application for Volanesorsen to the U.S. FDA
  16. Ionis Earns $40 Million SPINRAZA Regulatory Milestone Payment from Biogen
  17. Must-Know Developments for Ionis Pharmaceuticals
  18. How Akcea Therapeutics’ Volanesorsen Performed in 2Q17
  19. How Ionis’s Spinraza Performed in 2Q17

SEC Filings

  1. 8-K - Current report 171049664
  2. 8-K - Current report 171025738
  3. S-8 - Securities to be offered to employees in employee benefit plans 171015978
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171015883
  5. 8-K - Current report 171013237
  6. SC 13D - General statement of acquisition of beneficial ownership
  7. 8-K - Current report 17977089
  8. 8-K - Current report 17925095
  9. CT ORDER - Confidential treatment order 17920140
  10. 8-K - Current report 17879057